



PI3K: From Basic Science to Clinical Translation

Guest Editor:

Prof. Dr. Stephen Ward

Centre for Therapeutic
Innovation, Leukocyte Biology
Laboratory, Life Sciences
Department, University of Bath,
Claverton Down, Bath BA2 7AY,
UK

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editor

This Special Issue focuses on new functions and/or new discoveries in the regulation of phosphoinositide kinases and phosphatases. It encompasses the functions of inositol lipids and their molecular species, the consequences of a deregulation of phosphoinositide metabolism in human diseases, and the drugs that have been generated to interfere with their function in disease.

Basic science investigations continue to provide new insight into molecular medicine and clinical and translational sciences, while good progress has been achieved in PI3K pathway drug development, with several PI3K inhibitors now approved for oncology and several others in the approval and registration pipeline. *Pharmaceuticals* invites both reviews and original articles highlighting the molecular basis of PI3K in health and disease as well as opportunities for, and the development of, new therapeutics, quantitative diagnostic/prognostics, and strategies for targeting the PI3K pathway.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com